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Abstract
Background: Inadequate and poor quality outcome reporting in clinical trials is a well-documented problem that
impedes the ability of researchers to evaluate, replicate, synthesize, and build upon study findings and impacts
evidence-based decision-making by patients, clinicians, and policy-makers. To facilitate harmonized and transparent
reporting of outcomes in trial protocols and published reports, the Instrument for reporting Planned Endpoints in
Clinical Trials (InsPECT) is being developed. The final product will provide unique InsPECT extensions to the SPIRIT
(Standard Protocol Items: Recommendations for Interventional Trials) and CONSORT (Consolidated Standards of
Reporting Trials) reporting guidelines.
Methods: The InsPECT SPIRIT and CONSORT extensions will be developed in accordance with the methodological
framework created by the EQUATOR (Enhancing the Quality and Transparency of Health Research Quality) Network
for reporting guideline development. Development will consist of (1) the creation of an initial list of candidate
outcome reporting items synthesized from expert consultations and a scoping review of existing guidance for
reporting outcomes in trial protocols and reports; (2) a three-round international Delphi study to identify additional
candidate items and assess candidate item importance on a 9-point Likert scale, completed by stakeholders such as
trial report and protocol authors, systematic review authors, biostatisticians and epidemiologists, reporting guideline
developers, clinicians, journal editors, and research ethics board representatives; and (3) an in-person expert consensus
meeting to finalize the set of essential outcome reporting items for trial protocols and reports, respectively.
The consensus meeting discussions will be independently facilitated and informed by the empirical evidence
identified in the primary literature and through the opinions (aggregate rankings and comments) collected
via the Delphi study. An integrated knowledge translation approach will be used throughout InsPECT development to
facilitate implementation and dissemination, in addition to standard post-development activities.
Discussion: InsPECT will provide evidence-informed and consensus-based standards focused on outcome reporting in
clinical trials that can be applied across diverse disease areas, study populations, and outcomes. InsPECT will support
the standardization of trial outcome reporting, which will maximize trial usability, reduce bias, foster trial replication,
improve trial design and execution, and ultimately reduce research waste and help improve patient outcomes.
Keywords: Trial, Trial protocol, Reporting guideline, Outcome, Endpoint, SPIRIT, CONSORT
* Correspondence: nancy.butcher@sickkids.ca
1Child Health Evaluative Sciences, The Hospital for Sick Children Research
Institute, Toronto, Canada
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Butcher et al. Trials          (2019) 20:161 
https://doi.org/10.1186/s13063-019-3248-0
Background
Clinical trials, when appropriately designed, conducted,
and reported, are the gold standard study design for
generating evidence about treatment efficacy, safety,
effectiveness, and efficiency. To be able to critically
evaluate and use the results of a trial, however, readers
require complete, clear, and transparent information
with respect to what was planned, what was done, and
what was found [1]. Inadequate reporting of clinical
trials is well documented in the medical literature, even
with respect to basic methodological details such as the
definition of the primary outcome, specification of who
was blinded, and explanation of how trial sample size
was calculated [2–4]. Such incomplete reporting contri-
butes to significant and avoidable waste of health
research investment and impedes reproducibility [5, 6].
In an effort to improve trial reporting quality, repor-
ting guidelines have been developed to standardize the
reporting of clinical trial reports and their corresponding
protocols. These guidelines include Consolidated
Standards of Reporting Trials (CONSORT) [7], first
developed in 1996 and updated in 2010, for trial reports
published in academic journals, and Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT), developed in 2013, for trial protocols [8].
Numerous extensions have since been developed for
CONSORT and SPIRIT, refining their applications to
specific populations, study designs, interventions, and
contexts [9]. There is evidence that completeness of
trial reporting has improved since the development of
CONSORT, as shown by increased reporting of CONSORT
checklist items, particularly in journals that have endorsed
the guideline [10, 11]. CONSORT is now endorsed by
more than half of core medical journals, including The
Lancet, BMJ, JAMA, and the New England Journal of
Medicine as well as field-specific journals [12]. How-
ever, endorsement policies are not always clear; thus
increased effort by journals with respect to enforcement
of completion and evaluation of guideline adherence
may help further improve the current state of sub-
optimal trial reporting [10].
Despite the availability and implementation of these
well-established reporting guidelines for trials, significant
concerns regarding the quality of the reporting of trial
outcomes remain [13–18]. In the context of a clinical
trial, an outcome refers to what is being measured on
trial participants to examine the effect of exposure to a
health intervention [19]. SPIRIT and CONSORT provide
some general guidance on how to report outcomes
[7, 8], including pre-defined primary and secondary
outcomes, method of outcome assessment, and timing of
outcome assessment. However, outcome reporting
remains insufficient across disciplines and academic jour-
nals; key information about the selection process,
definition, measurement, and analysis of primary outcomes
is often missing or poorly reported [2, 3, 13, 20–24]. It has
been estimated that up to 60% of trials change, introduce,
or omit a primary outcome between protocol and publi-
cation of the trial report [20, 25–27], when a protocol is
even available for comparison. Less is known about
secondary outcomes, which may be even more prone to
bias and inadequate reporting [17]. As clinical trials are
“only as credible as their outcomes” [28], this lack of trans-
parency and completeness reduces or prevents reprodu-
cibility, critical appraisal, knowledge synthesis, and uptake
of trial results into clinical practice. Moreover, it enables
the introduction of bias into the medical literature by
facilitating selective reporting and outcome switching.
Although calls for improved reporting of trial outcomes
have been made [13, 14, 16, 29], to date it is unknown
what actually constitutes useful, complete reporting of
trial outcomes to knowledge users. No evidence- and/or
consensus-based detailed guidance currently exists for
authors to follow to ensure that their reporting is
complete, transparent, and replicable. SPIRIT requires
more information on trial outcomes to be reported than
CONSORT, but neither reflects, for example, the increas-
ingly widespread attempts to incorporate the patient voice
into clinical research. There is no requirement to report
why an outcome was selected, to provide a rationale for
the way the outcome was defined, or to describe the ac-
ceptability to patients of measuring the chosen outcome.
The advent of SPIRIT and CONSORT extensions for
patient-reported outcomes (PROs) [30, 31] as well as a
CONSORT extension for harms [32] represent important
steps in improving the reporting of trial outcomes. Re-
cently published guidelines for the content of statistical
analysis plans (SAPs) are also now available [33]. However,
more comprehensive and generic guidance that is applic-
able to all outcome types, disease areas, and populations is
still needed for trial protocols and published reports.
This protocol outlines the development process for an
internationally harmonized outcome reporting standard
for clinical trial protocols and reports, called the Instru-
ment for reporting Planned Endpoints in Clinical Trials
(InsPECT). Through an evidence-based and consensus-
based process, InsPECT will evaluate what constitutes
complete reporting of trial outcomes, with respect to
outcome selection, rationale, definition, measurement,
outcome analysis and its presentation, interpretation, and
transparent reporting of any outcome modifications be-
tween trial report and protocol. InsPECT will ultimately
form two evidence-based reporting extensions, one spe-
cific to trial protocols (SPIRIT extension) and one specific
to trial reports (CONSORT extension). The InsPECT ex-
tensions will be complementary to the work of the core
outcome set developers and the Core Outcome Measures
in Effectiveness Trials (COMET) Initiative, which provides
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information and guidance on which outcomes to measure
and report for particular health conditions [34].
Methods
The InsPECT extensions for SPIRIT and CONSORT will
be developed in accordance with the reporting guideline
development recommendations created by members of
the Enhancing the Quality and Transparency of Health
Research Quality (EQUATOR) Network [35] (Fig. 1).
The development process will thus consist of three pri-
mary phases: (1) generation of candidate reporting items
using a comprehensive and evidence-based approach,
including literature reviews [29, 36] and expert consul-
tations; (2) an international Delphi survey with key stake-
holders to identify any additional outcome reporting items
as well as to assess candidate item importance for each
extension; and (3) an in-person expert consensus meeting
to finalize the essential minimal set of outcome reporting
items in each extension and establish post-development
publication and dissemination activities.
Initial steps and project launch
InsPECT was initially conceived as part of a Global
Research in Paediatrics (GRiP) initiative in 2015 that was
undertaken to develop draft recommendations for the
selection and reporting of outcomes in pediatric phase II
and III drug trials [29]. Through this initiative, an initial
InsPECT checklist consisting of 13 candidate reporting
items was developed. As reported previously [29], these
items were developed based on the results of a sensitive
literature search that included all existing guidelines
from regulators (the US Food & Drug Administration
and the European Medicines Agency) and the World
Health Organization on the choice of outcomes in drug
trials and a targeted Medical Literature Analysis and
Retrieval System Online (MEDLINE) and Google search
for existing guidelines and recommendations on
outcome selection in phase II and III pediatric drug
trials, as well as pilot testing with pharmaceutical indus-
try partners and pediatric clinical trialists.
Recognizing that issues of poor outcome reporting are
not unique to pediatric trials, and that there is an inter-
national need for a harmonized reporting standard for
outcomes that complements existing trial reporting
guidelines, the InsPECT Group assembled in 2016 to
extend this initial work and develop comprehensive
standards for reporting outcomes in trial protocols and
reports that are generalizable and useful to trials for any
Fig. 1 Outline of the InsPECT (Instrument for reporting Planned Endpoints in Clinical Trials) development process
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population, using the EQUATOR Network reporting
guideline development recommendations [35]. The
InsPECT Group consists of 18 clinical trialists, clini-
cians, methodologists, knowledge synthesis experts, and
reporting guideline developers from around the world
(see Additional file 1: Table S1 for group members) with
representation from key outcome methods groups
(COMET, COSMIN [COnsensus-based Standards for
the selection of health Measurement INstruments], and
PORTal [Primary Outcomes Reporting in Trials]) and
reporting standard groups (CONSORT, SPIRIT, PRISMA
[Preferred Reporting Items for Systematic reviews and
Meta-Analyses], and TIDieR [Template for Intervention
Description and Replication]). InsPECT was registered
on the EQUATOR Network on 18 November 2015 and
officially launched in April 2017 after funding for
InsPECT development was secured by the InsPECT Group
from the Canadian Institutes of Health Research (CIHR).
Generation of candidate items
A comprehensive approach will be used to generate
candidate InsPECT items relevant to reporting outcomes
in clinical trial protocols and reports, through synthe-
sizing guidance and recommendations identified from
literature reviews [29, 36] and expert consultations with
the InsPECT Group. This will be led by the InsPECT
Operations team, composed of the InsPECT co-chairs
and project staff (see Additional file 1: Table S1). To
foster collaboration and knowledge translation, iterative
versions of the checklist items can be found on the
Open Science Framework at https://osf.io/zgpcy/. This
will be updated throughout InsPECT development.
To date, 70 preliminary candidate items have been
identified through consultations with members of the
InsPECT Group and a targeted examination of guidance
documents published after the GRiP version of the
InsPECT checklist was generated [29] (e.g., the SPIR-
IT-PRO and CONSORT-PRO reporting guidelines [30,
31]). With respect to InsPECT Group consultations,
checklist drafts were iteratively presented and modified
(i.e., addition of new candidate items and modification of
existing candidate items) following feedback from mem-
bers of the InsPECT Group obtained using in-person and
videoconference meetings and via Research Electronic
Data Capture (REDCap [37]) data management software
and/or email communications. As part of an applied
expert consultation, an early version of the candidate
items was applied by members of the InsPECT Operations
team (AC, AM) to a clinical trial protocol and a report
authored by members of the InsPECT Group (AP, SM,
respectively) [38, 39]. The observed reporting results were
discussed with the article authors in person, and the list of
items was modified and expanded as appropriate.
As the next step in generating the InsPECT candidate
item list, a comprehensive scoping review will be per-
formed to identify and synthesize all available existing
guidance on outcome reporting in clinical trials and pro-
tocols. Reporting recommendations extracted from iden-
tified guidance documents will be compared with the 70
existing candidate InsPECT items to support, refute, and
refine the preliminary InsPECT items with respect to
trial report and protocol reporting, and to identify
additional candidate InsPECT items. The protocol for
this scoping review is available elsewhere [36]. In brief,
documents that provide “explicit” guidance on trial out-
come reporting (“stated clearly and in detail, leaving no
room for confusion or doubt” such that the guidance
must specifically state that the information should be in-
cluded in a clinical trial protocol or report [40]) will be
searched for using (1) an electronic bibliographic data-
base search in MEDLINE and the Cochrane Method-
ology Register, (2) a gray literature search, (3)
documents gathered from the personal collections of
expert colleagues, and (4) reference list screening. The
results of this scoping review will be presented during
the InsPECT Delphi process and consensus meeting and
will be published in a peer-reviewed journal.
Delphi study
We will use a three-round electronic Delphi study using
a web-based questionnaire developed using REDCap
[37] with a sample of expert stakeholders to identify
additional candidate items and assess the importance of
each candidate item for inclusion in both clinical trial
protocols and clinical trial reports (Fig. 1). The Delphi
study will refine the InsPECT candidate item list for
evaluation at the consensus meeting. The Delphi method
is an iterative multistage process that allows for consen-
sus to be reached from a selection of disparate opinions,
through structured rounds of surveys coupled with
controlled feedback while maintaining anonymity [41–45].
Target study population and recruitment
We will engage international participants involved in the
design, conduct and oversight, publication, and appli-
cation of clinical trial reports and protocols to complete
the Delphi study. We will specifically target the recruit-
ment of trial report and protocol authors, reporting
guideline developers, biostatisticians and epidemiolo-
gists, systematic review/meta-analysis authors, clinicians,
journal editors, and research ethics board members.
Participants will be purposefully sampled using a com-
bined snowball sampling and criterion inclusion
approach [46]. Relevant groups, networks, organizations,
and individuals will be identified by the InsPECT Group
through their professional contacts, networks, and affi-
liations. Published participant lists from other relevant
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reporting guidelines as well as author lists of relevant
guidance documents identified from the scoping review
will also be examined to identify potential Delphi partici-
pants. The invitation to register to participate sent to the
initial list of invitees will include text that asks the re-
cipient to share the invitation with additional qualified
colleagues or relevant groups, networks, or organizations
that may be interested in participating in the InsPECT
Delphi study.
The inclusion criteria for participation in the Delphi
study are as follows: (1) completion of a brief web-based
Delphi registration survey, including agreement to
complete all three rounds of the Delphi study, and (2)
self-reported experience as indicated in the registration
survey in any of the following activities: authoring or
reviewing clinical trial protocol or reports; conducting
systematic reviews/evidence synthesis of clinical trials;
the design, conduct, and/or statistical planning of
clinical trials; the development of a reporting guideline
relevant to trial reporting; the development of a core
outcome set; and/or consultation of clinical trial
literature to inform clinical decision-making practices.
Any registrants who indicate that they have no experience
in any of these activities will be thanked for their interest
in participating but will not be invited to complete the
Delphi survey. There will be no geographical restrictions
on eligibility. Participation in each round of the Delphi
will be contingent on full completion of the prior Delphi
round. Those who complete the Delphi study will receive
an acknowledgement in published works for their contri-
butions, with their permission.
Registration to complete the Delphi study will be open
for approximately 1 month prior to Delphi Round 1.
Registrants will be asked to provide basic demographic
information, such as their job title, level of education,
whether they work in an industry or academic setting,
which participant group(s) they belong to (acknowledging
that many individuals may represent multiple participant
groups, e.g., both a trial author and a journal editor),
and their relevant experience (e.g., number of trial
reports written, number of trial reports reviewed).
There are no guidelines for determining the number of
participants in a Delphi study [45, 47]; we aim to
include a sample of experts who represent diverse dis-
ciplines, organizations, and opinions. We will seek to
recruit at least three to five people within each partici-
pant group; individuals who represent multiple stake-
holder categories will be placed in the group with fewer
participants when evaluating stakeholder representation
in the completed Delphi. This redistribution will take
place at the end of recruitment, according to patterns
observed during the registration period. The regis-
tration list for the Delphi study will be reviewed on an
ongoing basis, and recruitment strategies will be
adjusted as necessary to help ensure that the relative
distribution of expertise is appropriate prior to the
launch of the Delphi study.
Once the Delphi study begins, eligible participants will
be sent information that outlines InsPECT and the
Delphi process. All instructions and survey content will
be provided in English. Each round of the Delphi will
stay open for approximately three weeks. Delphi partici-
pants will be instructed that the InsPECT extensions
must each represent a minimal set of reporting items
that are essential for reporting outcomes in trial proto-
cols and reports, respectively. Reminder emails will be
sent approximately one week before each survey closes.
All participants will be allocated a unique ID number to
allow identification of individual responses during survey
rounds. The responses of each participant will remain
anonymous throughout each survey round and will be
analyzed anonymously. Only delegated members of the
InsPECT Operations team will know the identifiable
responses from each participant. Delphi participants will
not know the identities of the other Delphi participants
during the Delphi study. Participation in each survey will
be voluntary. Retention between Delphi surveys will be
encouraged by using recommended text [48] to convey
the importance of completing the entire Delphi study.
Delphi procedure
Each Delphi survey will require participants to evaluate
each candidate InsPECT item separately for importance
in inclusion in clinical trial protocols and clinical trial
reports, respectively, using a 9-point Likert scale with 1
to 3 signifying “limited importance”, 4 to 6 signifying
“important but not critical”, and 7 to 9 signifying “crit-
ical” [47, 49–51]. An additional “not my expertise” op-
tion will be included to accommodate stakeholder
groups that do not have the level of expertise to score all
items (e.g., candidate statistical reporting items). Each
item will be classified and presented as a new item
(i.e., item is not part of the SPIRIT 2013 Statement or the
CONSORT 2010 Statement), a revision item (i.e., concept
covered in part by SPIRIT 2013 and/or CONSORT 2010),
or an existing item (i.e., item or concept already part of
SPIRIT 2013 and/or CONSORT 2010) to provide an
opportunity for Delphi participants to confirm their
inclusion and provide comments on existing items.
Consensus will be assessed using the following criteria
[47, 52], consistent with methods and consensus criteria
used in the development of other recent reporting
guidelines [30, 53]:
1. Consensus in: ≥ 70% of participants scored the item
as “critical” (score 7 to 9) and < 15% scored the item
as of “limited importance” (score 1 to 3)
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2. Consensus out: ≥ 70% of participants scored the
item as of “limited importance” (score 1 to 3)
and < 15% scored the item as “critical” (score 7 to 9)
3. No consensus: All other results.
Delphi Round 1
Participants will be asked to score each candidate item
with respect to importance for inclusion in clinical trial
protocols and clinical trial reports, respectively, to obtain
a baseline measure of item importance. Free-text boxes
will provide space for participants to suggest additional
items and to provide comments on candidate items,
including explanations to support their ratings. New
item suggestions will be reviewed and integrated into
Round 2 by the InsPECT Operations team. Items
currently included in SPIRIT and/or CONSORT (“exis-
ting items”) that reach criteria for “consensus in” during
Round 1 will be considered confirmed for inclusion in
the final extensions and will not undergo additional
voting or discussion. All other items will be carried
forward to Round 2.
Delphi Round 2
Participants who completed Round 1 will be invited to
complete Round 2. Participants will be provided with
their Round 1 baseline score for each item and then
asked to consider the aggregate group results for each
item from Round 1 (e.g., median and percentage scoring
each of 1–9) as well as a summary of available results of
the scoping review (i.e., a summary of the empirical evi-
dence identified to support each candidate item, if any,
including any available evidence to support or refute
new items suggested in Round 1, as possible) when
re-scoring each item. The list of any existing SPIRIT
and/or CONSORT items already meeting criteria for
“consensus in” will also be provided for reference. A
summary of consolidated anonymized feedback from
free-text commentary will also be compiled from Round
1 and provided during Round 2. Free-text boxes will
provide space for participants to provide comments on
the candidate items. No additional items will be requested.
Items that meet criteria for “consensus out” in the
Round 2 results will be removed from the list of candi-
date items. Items that meet criteria for “consensus in” or
"no consensus" will move forward for consideration dur-
ing the consensus meeting. Any new items suggested in
Round 1 will move to Round 3 so that all items are eval-
uated twice. If consensus is obtained for all items during
Round 2, and no new items are added in Round 1,
then the Delphi study will terminate. If this occurs,
the Round 2 responses will be compiled into a sum-
mary report with the same metrics calculated for
Round 1 and disseminated to participants.
Delphi Round 3
Participants who completed Round 2 will be invited to
complete Round 3. Participants will be shown the aggre-
gate group results for each item from Round 2 and again
the summary of available results of the scoping review,
and their own score from Round 2. The list of any items
already meeting criteria for any consensus status will
also be provided. A summary of consolidated anon-
ymized feedback from free-text commentary will also be
compiled and provided from Round 2. Participants will
be instructed to consider the provided information and
to re-score each item. Free-text boxes will provide space
for participants to provide comments on the candidate
items. No additional items will be requested.
After completion of Round 3, the same analysis proce-
dures as described in Round 2 will be employed. Items
that meet criteria for “consensus out” from the Round 3
results will be removed from the list of candidate items.
Items that meet criteria for “consensus in” as well as any
items that did not achieve consensus will move forward
for consideration during the consensus meeting.
In preparation for the consensus meeting, the
InsPECT Operations team will map the remaining can-
didate items from the Delphi results into draft SPIRIT
and CONSORT InsPECT extensions. Candidate items
will be merged, and/or their phrasing clarified at this
time, considering the stakeholder comments identified
during the Delphi surveys. Invited consensus meeting
participants will receive pre-meeting materials in pre-
paration for the consensus meeting, which will include
the drafted SPIRIT and CONSORT InsPECT candidate
items, accompanied by the aggregated Delphi results
and evidence summaries.
Consensus meeting
A two day in-person consensus meeting will be held in
2019 in Toronto, Canada. Following recommended pro-
cedures for reporting guideline development [35], the
primary goal will be to obtain expert group consensus
on which items will be included with their finalized
wording in the final InsPECT extensions for SPIRIT and
CONSORT, respectively, through examination and dis-
cussion of the refined candidate item list resulting from
the Delphi. This will be guided by the empirical evidence
identified from the scoping review and through the
opinions collected pre-meeting from the Delphi survey.
The secondary goal will be to discuss and establish pub-
lication and dissemination strategies.
Participants
All members of the InsPECT Group will be invited to
participate. We will aim to achieve a sample of 15 to 20
participants. Additional colleagues and/or Delphi
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participants with appropriate expertise may also be pur-
posefully sampled and invited, if necessary to achieve ad-
equate representation of the stakeholder groups at the
consensus meeting.
Procedure
The consensus meeting will be led by the InsPECT
chairs and an experienced independent moderator. Tele-
conferencing will be available for those unable to attend
in person. The meeting will begin by presenting an over-
view of the InsPECT development process, the meeting
procedures, and the meeting materials. Each candidate
item for the SPIRIT and CONSORT InsPECT extensions
will be presented, accompanied by the Delphi results
and the evidence summaries. Moderated round table
discussions of each item will follow. After discussion,
anonymous voting on each item will be conducted to
ensure that all voices are heard equally and for transpa-
rency in the decision-making process. Voting options for
each candidate item within each guideline extension
such as “Include in final checklist”, “Exclude from final
checklist”, “Merge with another item”, and “Unsure” will
be provided.
Items will reach consensus for inclusion when ≥ 70%
of participants vote “Include in final checklist” for the
item. Items will not be eligible for inclusion and will be
excluded from future rounds of voting if ≥ 70% of parti-
cipants vote “Exclude from final checklist”. For any items
that do not reach consensus after the first round of
voting, another moderated round table discussion will
be held, followed by a second vote. This process will
continue until either all items have reached consensus,
or time has run out. All round table discussions will be
audio recorded. In the event that consensus was not
reached on all items at the conclusion of the meeting,
the final decision for inclusion of remaining items will
be made by members of the InsPECT Executive and
Operations team.
Publication and dissemination strategies will also be
discussed at the consensus meeting. Topics may include
publication strategies, maximizing journal endorsement,
end user adherence, evaluation strategy, handling
criticism, and social media/web-based presence [35].
Knowledge translation and dissemination
An integrated knowledge translation (iKT) framework
for InsPECT was developed in accordance with the
CIHR Guide to Knowledge Translation Planning at
CIHR: Integrated and End-of-Grant Approaches [54].
iKT is defined as an ongoing relationship between
researchers and decision-makers for the purpose of
engaging in a mutually beneficial research project
[55, 56]. Our strategy involves progress updates and
feedback from members of the InsPECT Group, who are
collectively representative of the project stakeholder
groups. This includes at least one meeting with each
member regarding project scope and methods, the oppor-
tunity to provide written feedback on an initial draft ver-
sion of the checklist, and an invitation to review and
provide feedback on the study protocol (this document).
Ongoing iKT effort with the larger scientific community
includes maintaining an active presence on social media
(e.g., @InsPECT2019 on Twitter), maintaining the
InsPECT website [57], and presenting InsPECT methods
and preliminary results at international, national, and local
conferences. InsPECT project materials are publicly avai-
lable on the Open Science Framework [58].
End-of-grant activities will include publication of the
InsPECT extensions for the SPIRIT and CONSORT
reporting guidelines and applicable explanation and
elaboration (E&E) documents. The E&Es will provide
the background, rationale, and justification for each
reporting item, as well as examples of good reporting.
We will aim to link the InsPECT extensions via key rele-
vant websites, such as the EQUATOR Network website
[9], the SPIRIT Statement website [59], the CONSORT
Statement website [60], and the COMET website [34].
Journals that currently endorse CONSORT and SPIRIT
will be approached for InsPECT extension endorsement.
SPIRIT and CONSORT are endorsed by roughly 100 and
600 journals, respectively [12, 61]. SPIRIT is also
endorsed by regulators, funders/industry, trial groups, aca-
demic institutions, contract research organizations, and
patient groups [61]. End-user feedback will be sought and
incorporated, including feedback from patient groups, as
appropriate, post-development. We will also follow
other dissemination strategies established during the
consensus meeting.
Discussion
InsPECT will provide guidance on how to completely
report any type of outcome in clinical trial reports and
protocols. The development and implementation of the
InsPECT extensions to CONSORT and SPIRIT have the
potential to help harmonize and standardize outcome
reporting across published trials reports and protocols,
which will help facilitate trial reproducibility, trans-
parency, and critical appraisal. While the emphasis of
InsPECT is on clinical trials, the resultant guidance is
expected to be generally applicable to all evaluative
study designs, including observational studies and other
study designs; future studies may develop specific
InsPECT extensions for other study designs. The adop-
tion and implementation of the InsPECT extensions will
facilitate systematic reviews and meta-analyses by
helping to standardize outcome reporting in the primary
studies and promises to help reduce, or at least better
Butcher et al. Trials          (2019) 20:161 Page 7 of 10
identify, selective reporting between protocols and trial
reports. The InsPECT extensions will also help increase
the value of core outcome sets, which are increasingly
being developed and implemented [65], by helping to
enhance the clear and reproducible reporting of the core
outcomes across trials and trial documents.
We expect that our implementation of a consensus-
based and iKT approach will lead to improved clarity
and acceptance and use of the InsPECT extensions
among the broader research community. One poten-
tial challenge in the development of InsPECT is
maintaining an optimal balance between usability and
comprehensiveness. Different types of outcomes will
require different types of information to be reported
to enable reproducibility and transparency, and may
also vary depending on the trial context including the
intervention and population. For example, reporting
on outcome assessor training may be quite relevant
for some clinician-reported outcomes, but less so for
biological markers such as cholesterol levels measured
using standard laboratory processes. InsPECT will
identify the minimal level of information required to
be reported. Involving a large, diverse, and inter-
national group of stakeholders in the development of
InsPECT may increase usability among the broader
research community. As of September 2018, an initial
list of InsPECT candidate items has been generated
and the scoping review is ongoing. The Delphi study
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